All Updates

All Updates

icon
Filter
Partnerships
PreciseDx and COTA partner to enhance AI-powered precision breast cancer diagnostic
Precision Medicine
May 29, 2024
This week:
M&A
Funding
TravelPerk raises USD 135 million in debt funding for expansion; acquires AmTrav
Travel Tech
Yesterday
Product updates
Apple announces Apple Pay Later shutdown
Buy Now, Pay Later
Jun 17, 2024
Management news
Velo3D appoints Brad Kreger as permanent CEO
Additive Manufacturing
Jun 17, 2024
Partnerships
Perplexity partners with SoftBank for AI search engine promotion in Japan
Generative AI Applications
Jun 17, 2024
Product updates
Runway launches Gen-3 Alpha for generating video clips
Generative AI Applications
Jun 17, 2024
Product updates
Adobe integrates Firefly into Acrobat with chat support across multiple documents in Acrobat AI Assistant
Generative AI Applications
Jun 17, 2024
Funding
Amplify Life raises USD 20 million in Series B to expand product suite
InsurTech: Personal Lines
Jun 17, 2024
Funding
Tinybird raises USD 30 million in Series B funding to improve real-time data analytics platform
Data Infrastructure & Analytics
Jun 17, 2024
Partnerships
The EVERY Company collaborates with Grupo Palacios to develop hen-less omelets
Plant-based Dairy & Egg
Jun 17, 2024
Partnerships
Believer Meats partners with AGWA to propel cultivated meat industry in MENA region
Cell-cultured Meat
Jun 17, 2024
Precision Medicine

Precision Medicine

May 29, 2024

PreciseDx and COTA partner to enhance AI-powered precision breast cancer diagnostic

Partnerships

  • Precise DX and COTA have partnered with Baptist Health South Florida to assess the performance of PreciseDx's AI-enabled PreciseBreast (PDxBr) test for assessing the risk of invasive breast cancer (IBC) recurrence.

  • The validation assessment will compare PDxBr’s results to traditional pathology reviews and 21-gene assay results. If the validation study is successful, Baptist Health has agreed to offer the test to its patients with IBC to expand access to the product within the oncology sector. The test is claimed to produce results in 48 hours at an 80% lower cost than conventional pathology solutions. 

  • New York-based PreciseDx leverages advanced AI to analyze samples and provide patient-specific risk information. The company's key offerings include the PreciseDx platform, which helps patients and healthcare practitioners understand breast cancer diagnosis and determine personalized treatment plans.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.